(Q47435734)

English

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). (English)

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

0 references

1 reference

based on heuristic

inferred from title

Catherine Thieblemont

1

object named as

Catherine Thieblemont

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

author name string

Fadhela Bouafia

2

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Emmanuel Hornez

3

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Charles Dumontet

4

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Sophie Tartas

5

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Daciana Antal

6

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Bernard Lemieux

7

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Catherine Traullé

8

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Daniel Espinouse

9

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Gilles Salles

10

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Bertrand Coiffier

11

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

publication date

1 April 2004

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Leukemia & Lymphoma

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

45

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

711-714

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

4

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1080%2F10428190310001615675

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1080%2F10428190310001615675

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1080%2F10428190310001615675

21 January 2018

Identifiers

10.1080/10428190310001615675

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/15160944

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47435734&oldid=1783755996"